Acorda Therapeutics: Parkinson Disease trials

The registry lists 13 Parkinson Disease studies with Acorda Therapeutics as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 3Phase 2 5Phase 3 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.TerminatedNCT03051607Phase 3Results posted
• Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsTerminatedNCT02453386Phase 3Results posted
• Randomized Safety Study of CVT-301 Compared to an Observational Control GroupCompletedNCT02352363Phase 3Results posted
• SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)CompletedNCT02258152Phase 2Results posted
• Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesCompletedNCT02242487Phase 3Results posted
• Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesCompletedNCT02240030Phase 3Results posted
• Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)CompletedNCT03887884Phase 1
• A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) TabletsCompletedNCT02812394Phase 1
• A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)CompletedNCT02807675Phase 1
• Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF EpisodesCompletedNCT01777555Phase 2
• Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" EpisodesCompletedNCT01617135Phase 2
• Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing OffCompletedNCT01283594Phase 2/3
• Study to Evaluate SYN115 in Parkinson's DiseaseCompletedNCT00605553Phase 2